How to evaluate a vendor's AI claims before you buy

This happens constantly in 2026. Pharma has become a magnet for AI vendors because the stakes (a single Phase III trial can cost $50-100 million, per widely cited industry estimates) make even a marginal improvement sound worth millions. That same math makes it worth your time to interrogate the claim before signing.

Why pharma-grade validation is different

Most AI vendors selling into other industries validate on general-purpose or public datasets. Pharma has three properties that make this insufficient:

• Regulatory exposure. If the AI tool touches trial design, safety signal detection, or submission content, it may eventually intersect with FDA (U.S. Food and Drug Administration) or EMA (European Medicines Agency) review. A model trained on unrepresentative data can produce recommendations that don't hold up under regulatory scrutiny.
• Data scarcity and bias. Clinical trial data is smaller, messier, and more heterogeneous than e-commerce or ad-tech data. A model that performs well on 50,000 well-labeled retail transactions may collapse on 500 poorly harmonized patient records.
• Consequences of error. A bad product recommendation costs a sale. A bad enrollment prediction can delay a trial by months or contribute to a design flaw that harms patients or wastes a full clinical program.

This is why "it works" is not a sufficient claim. You need to know: worked on what, measured how, compared to what baseline.

The five questions that expose a weak claim

1. "What data was this trained and validated on?"

Ask for the source, size, and provenance of training and validation sets. Red flag: vague answers like "a large proprietary dataset of clinical trials." Good answer: "trained on X historical trials from [named data source, e.g., ClinicalTrials.gov, or a licensed real-world data provider], validated on a held-out set of Y trials the model never saw."

ClinicalTrials.gov is the U.S. National Library of Medicine's public registry of trials and a common benchmark source; if a vendor claims to use "real-world trial data" but can't name a registry, license, or data partner, push harder.

2. "What's the baseline you're beating?"

A 30% enrollment acceleration claim is meaningless without a comparator. Beating what: a random site selection process, an experienced clinical operations team's manual planning, or last year's average enrollment timeline across a similar therapeutic area? Ask for the counterfactual explicitly.

3. "Was this validated prospectively or only retrospectively?"

Retrospective validation (testing the model on historical trials it wasn't trained on) is a reasonable first step but is prone to hindsight bias, since researchers know how those trials actually turned out. Prospective validation (the model made a prediction before the outcome was known, in a live or simulated live setting) is the stronger evidence. Most vendor pitches in 2026 still lean heavily on retrospective numbers. That's not disqualifying, but it should shape your confidence level and the size of your pilot.

4. "Does performance hold across subgroups?"

A model that performs well on average but poorly for rare diseases, specific geographies, or underrepresented patient populations creates real risk. This matters directly for clinical trial diversity requirements under FDA guidance on diversity action plans (finalized guidance, 2024) and similar EMA expectations. Ask for subgroup-level performance, not just an aggregate accuracy number.

5. "What happens when the model is wrong?"

Ask about the failure mode. Does the tool flag its own uncertainty? Is there a human-in-the-loop checkpoint before a recommendation becomes a decision? A vendor with a mature product will have a clear answer. A vendor still in early-stage selling will often deflect to "the AI is just a decision supportdecision supportTechnologies and processes that turn raw data into actionable insights via reporting, dashboards and analysis, so teams can decide based on facts rather than intuition.View full definition → tool," which is fine, but only if your internal process actually treats it that way.

A simple framework: the four-layer check

When you get the vendor's technical answers, run them through this stack:

If a vendor can't answer Layer 1 with specifics, don't bother evaluating Layers 2-4. Weak foundations invalidate everything built on top.

What good evidence actually looks like

Compare two vendor claims:

Weak: "Our model predicts trial dropout risk with 85% accuracy."

Strong: "Our model predicts 90-day dropout risk with an AUC (Area Under the Curve, a standard measure of a classification model's discriminative power, where 0.5 is random guessing and 1.0 is perfect) of 0.78 on a held-out validation set of 12,000 patients across four therapeutic areas, benchmarked against a logistic regression baseline that achieved 0.65. Performance was consistent (AUC within 0.03) across age and sex subgroups but dropped to 0.68 for patients over 75, which we flag in the tool's output."

The second version is falsifiable, specific, and honest about limitations. That honesty is itself a signal of vendor maturity.

Worked example: sizing a pilot before a full purchase

Suppose a vendor claims their site-selection AI improves enrollment speed by 25%, based on retrospective analysis of 40 trials. Before committing to an enterprise contract, size a pilot:

• Pick 3-5 upcoming trials in a single therapeutic area (controls for confounding by disease complexity).
• Run the AI recommendation in parallel with your standard clinical operations process, without letting the AI override the human decision.
• Compare actual enrollment timelines against your last 3-5 comparable trials (your internal baseline, not the vendor's).
• Predefine the success threshold before the pilot starts, for example: "If AI-recommended sites enroll at least 15% faster on average, we proceed to a broader rollout."

This costs you a few months and limited budget, versus a multi-year enterprise license based on a slide deck.

Reading the regulatory signal correctly

Vendors sometimes imply regulatory approval when none exists. Be precise about the difference:

• FDA clearance/approval applies to specific medical devices or Software as a Medical Device (SaMD), not general-purpose analytics or trial-design tools. Most AI trial-design and operations tools are not regulated as medical devices at all.
• No FDA "AI certification" program exists for enterprise clinical operations software as of 2026. If a vendor claims their AI is "FDA-approved" for a trial-design or enrollment tool, ask exactly what was submitted and cleared, because the claim is very likely either false or refers to something narrower than implied.

For context on how the FDA is approaching AI in the drug development lifecycle specifically (distinct from AI medical devices), see the FDA's discussion paper on AI in drug and biological product development, a useful primer on where the agency's thinking stood as this space evolved.

Key Takeaways

• Demand specifics on training data, validation method, and baseline comparator before evaluating any performance number; vague answers are the strongest red flag.
• Prefer prospective validation over retrospective-only claims, and ask explicitly which one you're being shown.
• Check subgroup performance, not just aggregate accuracy, especially given regulatory expectations around trial population diversity.
• No blanket "FDA-approved AI" status exists for trial-design or operations software; verify precisely what, if anything, was actually reviewed by a regulator.
• Run a small, predefined pilot with your own historical baseline before committing to a full contract; it's cheaper than discovering a vendor's claims don't generalize after you've already signed.